

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## DIAGNOSTICS ASSESSMENT PROGRAMME

### Equality impact assessment – Guidance development

#### EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

One equality issue was identified during scoping. This relates to the frequency of EGFR-TK mutations being highest among Asian women who have tumours with adenocarcinoma histology, but have never smoked. This issue did not need to be addressed by the Committee as EGFR-TK mutation testing is carried out on all eligible patients irrespective of gender, ethnicity and smoking status, to ensure that all eligible patients who could benefit from treatment with an anti-EGFR TKI are identified (as recommended in technology appraisal 192).

2. Have any other potential equality issues been raised in the second assessment subgroup meeting (if held) and in the evidence assessment and analysis report, and, if so, how has the Committee addressed these?

No additional potential equality issues were identified.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No additional equality issues were identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for

the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No.

7. Have the Committee's considerations of equality issues been described in the diagnostics consultation document, and, if so, where?
No.

**Approved by Associate Director (name):** Nick Crabb

**Date:** 01/08/2013

## Diagnosics guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the Committee's considerations of equality issues been described in the diagnostics guidance document, and, if so, where?

No.

**Approved by Programme Director (name):** Mirella Marlow

**Date:** 01/08/2013